Direct inhibition of IL-17 through monoclonal antibodies (e.g., secukinumab and ixekizumab) or of IL-17R, (brodalumab) has been approved for treating autoimmune diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis (161, 162). This evidence concerns the gene IL17A and ankylosing spondylitis.